Kintara Therapeutics Files 8-K

Ticker: HURA · Form: 8-K · Filed: Sep 24, 2024 · CIK: 1498382

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: KTRA

TL;DR

KINTARA THERAPEUTICS (KTRA) filed an 8-K on 9/24/24 covering Reg FD and financials.

AI Summary

Kintara Therapeutics, Inc. filed an 8-K on September 24, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc., is incorporated in Nevada and headquartered in San Diego, California.

Why It Matters

This filing provides official updates on the company's regulatory disclosures and financial reporting, which are crucial for investors to assess its current status and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate, significant operational changes.

Key Numbers

Key Players & Entities

FAQ

What specific events are detailed in the Regulation FD Disclosure section of this 8-K?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.

What types of financial statements and exhibits are included with this 8-K filing?

The filing states 'Financial Statements and Exhibits' are included, but the specific nature or content of these documents is not detailed in the provided text.

When was Kintara Therapeutics, Inc. previously known as DelMar Pharmaceuticals, Inc.?

The date of name change from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. was January 23, 2013.

What is the principal executive office address for Kintara Therapeutics, Inc.?

The principal executive offices are located at 9920 Pacific Heights Blvd, Suite 150, San Diego, California, 92121.

What is the SIC code for Kintara Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Kintara Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,798 words · 7 min read · ~6 pages · Grade level 15.9 · Accepted 2024-09-24 08:30:08

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On or about September 24, 2024, Kintara Therapeutics, Inc. (" Kintara ") distributed a letter to certain stockholders regarding the Special Meeting of Stockholders (the " Special Meeting ") to allow for completion of the proposed merger (the " Merger ") with TuHURA Biosciences, Inc. (" TuHURA "). A copy of the letter is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the " SEC "), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing. Additional Information about the Proposed Merger and Where to Find It This Current Report on Form 8-K does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This Current Report on Form 8-K relates to the proposed Merger of Kintara and TuHURA. In connection with the proposed Merger, Kintara has filed a Registration Statement on Form S-4 and a definitive proxy statement and a final prospectus of Kintara (the " proxy statement/prospectus "). This registration statement was declared effective on August 13, 2024 and Kintara has filed or may file other documents regarding the proposed Merger with the SEC. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE DEF

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the communication attached hereto as Exhibit 99.1 contain forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied, including the failure to obtain Kintara stockholder approval for the proposed Merger; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that cou

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Letter to Kintara Therapeutics, Inc. Stockholders.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: September 24, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing